University of Michigan

University of California

Dennis J Hartigan-O'Connor

Jeffrey S Chamberlain

Michael S German

Andrea Amalfitano

John L Rubenstein

Rajendra Kumar-Singh

Lori Sussel

Roger A Pedersen

Maike Sander

Juanito J Meneses

Michael A Hauser

Peter Barry

Joseph Dutra

Jesse Deere

The present invention provides compositions and methods for inducing immune responses in subjects using HV-based vectors that can be grown in single celled organisms and administered in their nucleic acid form.

Vaccination using herpesvirus genomes in nucleic acid form

The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.

Production of viral vectors

The present invention features mouse models for Nkx-2.2 gene function and for Nkx-6.1 gene function, wherein the transgenic mouse is characterized by having a defect in Nkx-2.2 gene function or a defect in Nkx-6.1 gene function (where, because Nkx-2.2 acts upstream of Nkx-6.1, a defect in Nkx-2.2 gene function affects Nkx-6.1 gene function) and by having a decreased number of insulin-producing cells relative to a normal mouse. Where the transgenic mouse contains a defect in Nkx-2.2 gene function, the mouse is further characterized by a decreased number of serotonin-producing cells relative to a normal mouse. The transgenic mice may be either homozygous or heterozygous for the Nkx-2.2 or Nkx-6.1 defect.

NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression,

The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These 'gutted' vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.

Adenovirus vectors

Growing community of inventors

Ann Arbor, MI, United States of America

Dennis J Hartigan-O'Connor